{"id":"imm-101","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Chills"}]},"_chembl":{"chemblId":"CHEMBL4650475","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"IMM-101 is a heat-killed whole cell vaccine derived from Mycobacterium obuense that acts as an immunological adjuvant. It is designed to prime and activate innate and adaptive immune responses, enhancing the body's ability to recognize and attack cancer cells. The vaccine is being developed as a combination therapy to potentiate checkpoint inhibitors and other immunotherapies.","oneSentence":"IMM-101 is an immunotherapeutic vaccine that activates the immune system against Mycobacterium obuense to enhance anti-tumor immunity.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:15:35.334Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced melanoma (in combination with checkpoint inhibitors)"},{"name":"Non-small cell lung cancer (in combination with checkpoint inhibitors)"}]},"trialDetails":[{"nctId":"NCT04442048","phase":"PHASE3","title":"Immunization With IMM-101 vs Observation for Prevention of Respiratory and Severe COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure","status":"COMPLETED","sponsor":"Canadian Cancer Trials Group","startDate":"2020-10-01","conditions":"Cancer, Covid-19","enrollment":195},{"nctId":"NCT06498518","phase":"PHASE2","title":"A Trial of Gemcitabine, Pembrolizumab and IMM-101 as First Line Treatment in Patients With Metastatic Pancreatic Cancer","status":"WITHDRAWN","sponsor":"Karen Carty","startDate":"2024-06-17","conditions":"Neoplasms Pancreatic","enrollment":""},{"nctId":"NCT05118724","phase":"PHASE2","title":"Atezolizumab in Patients With MSI-h/MMR-D Stage II High Risk and Stage III Colorectal Cancer Ineligible for Oxaliplatin","status":"ACTIVE_NOT_RECRUITING","sponsor":"AIO-Studien-gGmbH","startDate":"2021-12-10","conditions":"Colorectal Cancer","enrollment":80},{"nctId":"NCT03009058","phase":"PHASE1, PHASE2","title":"Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer","status":"TERMINATED","sponsor":"Immodulon Therapeutics Ltd","startDate":"2017-05-31","conditions":"Metastatic Cancer","enrollment":2},{"nctId":"NCT01539824","phase":"PHASE2","title":"A Study of IMM-101 in Combination With Radiation Induced Tumour Necrosis in Colorectal Cancer","status":"COMPLETED","sponsor":"Immodulon Therapeutics Ltd","startDate":"2012-05-30","conditions":"Metastatic Colorectal Cancer","enrollment":12},{"nctId":"NCT03711188","phase":"PHASE2","title":"A Study of IMM-101 in Combination With Checkpoint Inhibitor Therapy in Advanced Melanoma","status":"COMPLETED","sponsor":"Immodulon Therapeutics Ltd","startDate":"2018-10-04","conditions":"Melanoma","enrollment":16},{"nctId":"NCT01559818","phase":"PHASE1, PHASE2","title":"A Long Term Follow up Study for Patients Who Previously Took Part in the Phase I Study IMM-101-001","status":"TERMINATED","sponsor":"Immodulon Therapeutics Ltd","startDate":"2012-02","conditions":"Malignant Melanoma","enrollment":10},{"nctId":"NCT01303172","phase":"PHASE2","title":"A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"Immodulon Therapeutics Ltd","startDate":"2011-06","conditions":"Advanced Pancreatic Cancer","enrollment":110},{"nctId":"NCT04137822","phase":"","title":"Expanded Access Program Using IMM-101 for Patients With Advanced Pancreatic Cancer","status":"NO_LONGER_AVAILABLE","sponsor":"Impatients N.V. trading as myTomorrows","startDate":"","conditions":"Pancreas Cancer, Pancreatic Cancer, Pancreatic Cancer Stage IV","enrollment":""},{"nctId":"NCT01308762","phase":"PHASE1","title":"A Clinical Study, to Evaluate the Safety and Tolerability of Intradermal IMM-101 in Adult Melanoma Cancer Patients","status":"COMPLETED","sponsor":"Immodulon Therapeutics Ltd","startDate":"2010-03","conditions":"Melanoma","enrollment":19}],"_emaApprovals":[],"_faersSignals":[{"count":5,"reaction":"CEREBELLAR INFARCTION"},{"count":5,"reaction":"URINARY TRACT INFECTION"},{"count":3,"reaction":"DIZZINESS"},{"count":2,"reaction":"BLOOD ALKALINE PHOSPHATASE INCREASED"},{"count":2,"reaction":"HAEMOGLOBIN DECREASED"},{"count":2,"reaction":"RED BLOOD CELL COUNT DECREASED"},{"count":2,"reaction":"VOMITING"},{"count":1,"reaction":"ANAEMIA"},{"count":1,"reaction":"BILIARY SEPSIS"},{"count":1,"reaction":"BLOOD CREATININE INCREASED"}],"_approvalHistory":[],"publicationCount":12,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Heat-killed whole cell M. obuense","Heat killed whole cell M. obuense National Collection of Type Cultures (NCTC) 13365","Heat killed whole cell Mycobacterium obuense (M. obuense)","Heat killed M. obuense (NCTC 13365)"],"phase":"phase_3","status":"active","brandName":"IMM-101","genericName":"IMM-101","companyName":"Immodulon Therapeutics Ltd","companyId":"immodulon-therapeutics-ltd","modality":"Biologic","firstApprovalDate":"","aiSummary":"IMM-101 is an immunotherapeutic vaccine that activates the immune system against Mycobacterium obuense to enhance anti-tumor immunity. Used for Advanced melanoma (in combination with checkpoint inhibitors), Non-small cell lung cancer (in combination with checkpoint inhibitors).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":4,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}